$7.6B
Total sales of cystic fibrosis medicines per year
Novel Small Molecule Drug Platform
Fighting lung infections with a novel compound class inspired from plant-derived isolates
At Sequoia Vaccines, we've discovered two distinct classes of plant compounds that inhibit the swarming biofilms of gram-negative bacteria. We have prepared hundreds of analogs via synthesis, resulting in leads, which we are continuing to optimize.
| Indication or Program | Preclinical | Phase 1 | Phase 2 | Phase 2/3 | Market |
|---|---|---|---|---|---|
Novel small molecule drug platformCystic Fibrosis Lung Infections |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 2/3 Phase not started
|
Market Phase not started
|
Cystic fibrosis market overview
Source: Vertex Pharmaceuticals, Form 10-K, December 31, 2021. “Our net product revenues and the vast majority of our total revenues are derived from the sale of CF medicines.”
How it works
Preventing infections by targeting cystic fibrosis biofilms
Our compounds are optimized from plant-based molecules that inhibit PilY1, a master regulator of P. aeruginosa virulence, and type IV pili, a mediator for many bacterial functions that attach and colonize human airway tracheobronchial epithelial cells.
Our leads are synergistic with certain antibiotics against swarming biofilm populations of gram-negative bacteria.
By inhibiting P. aeruginosa biofilms, we believe our compounds have the potential to reduce mucoids, prevent infections, and potentially improve the lives of patients.
Preclinical studies
Analogs of our novel small molecule platform demonstrate potential in benefitting lung functions in cystic fibrosis
Two independent academic laboratories revealed that P. aeruginosa utilizes PilY1, a master regulator of P. aeruginosa virulence, and type IV pili, a mediator for many bacterial functions, attach and colonize human airway tracheobronchial epithelial cells.
We believe that by targeting and inhibiting PilY1 and type IV pili of P. aeruginosa, a further optimized SEQ-1150 can potentially reduce the deterioration of lung function in cystic fibrosis patients. In our research, we have demonstrated that our leads can potentially inhibit PilY1 and also type IV pili, and thus inhibit biofilm formation and spreading.
P. aeruginosa isolated from the lungs of a cystic fibrosis patient
Lawrence et al. Bioorganic & Medicinal Chemistry. 2020, 28 (5):115229
SEQ-400
For recurrent UTIs
Our lead program, SEQ-400, is a FimH vaccine for the prevention of recurrent urinary tract infections (UTIs).
SEQ-1274 Drug Platform
For ovarian/other cancers
SEQ-1274 and analogs are small molecules with the potential to treat patients with ovarian and other cancers.
Research & publications
Sequoia’s research and development studies and programs have been published in more than 50 peer-reviewed scientific publications. We invite you to learn more about our science.
View publications